Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Assets: 2019-2024

Historic Assets for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $349.6 million.

  • C4 Therapeutics' Assets fell 29.40% to $265.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.5 million, marking a year-over-year decrease of 29.40%. This contributed to the annual value of $349.6 million for FY2024, which is 7.13% down from last year.
  • Per C4 Therapeutics' latest filing, its Assets stood at $349.6 million for FY2024, which was down 7.13% from $376.5 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Assets registered a high of $506.8 million during FY2021, and its lowest value of $349.6 million during FY2024.
  • Over the past 3 years, C4 Therapeutics' median Assets value was $376.5 million (recorded in 2023), while the average stood at $385.6 million.
  • In the last 5 years, C4 Therapeutics' Assets surged by 238.35% in 2020 and then decreased by 14.98% in 2022.
  • Over the past 5 years, C4 Therapeutics' Assets (Yearly) stood at $400.1 million in 2020, then climbed by 26.65% to $506.8 million in 2021, then dropped by 14.98% to $430.8 million in 2022, then fell by 12.62% to $376.5 million in 2023, then dropped by 7.13% to $349.6 million in 2024.